Can Pfizer Vaccine be Secured in Korea?

<Anchor> If

you have any questions about this vaccine, I will ask a medical reporter Cho Dong-chan, a specialist.

[Cho Dong-chan / Medical reporter (specialist): Korea is not an underdeveloped country.

It is not advantageous in securing quantity because it does not participate in clinical trials.

However, this vaccine can be commercialized only when a distribution system called cold chain is in place, but it is likely to be difficult to commercialize in many underdeveloped countries.

Since Korea has a cold chain, there is some room, but this year will be difficult.

It will be possible next year, but it seems difficult to secure enough supplies.

You should also pay attention to other vaccines.]

[Cho Dong-chan/medical journalist (specialist): Currently, two types of vaccine clinical trials are currently in progress in Korea.

About 150 out of 30,000 people who got the vaccine and the fake drug had to be confirmed, so you can tell how many of the people who got the vaccine and how many of the people who got the fake drug were infected.

However, the number of confirmed cases in Korea is very small, so the speed of clinical trials is very slow.

It is expected to be completed by the end of next year at the earliest.]

is the'U.S.

[Dong-Chan Cho / Medical Reporter (Specialist): Antibody therapy approved by the United States is for patients with mild corona19. When administered to mild corona patients, the rate of exacerbation to severe gastric disorders was significantly lower than 1.6% and 6.3% compared to the sham drug group. The problem was that it didn't work for severely ill patients. Unlike mild patients, severe patients already have a lot of antibodies in their bodies, so it would be useless if more antibodies were administered from the outside.]

[Dong-Chan Jo/Medicine Reporter (Specialist): Patients with severe corona19 have adverse effects of the virus itself, but in the process of fighting the virus, inflammatory reactions and autoimmune reactions significantly worsen symptoms. So, for severely ill patients, opinions gathered that it would be better to treat a combination of drugs that suppress inflammation and immunity with antiviral and antibody treatments that suppress the virus rather than a single drug. Research is actively underway.]